Emergent Biosolutions (NYSE:EBS) will be issuing its quarterly earnings data after the market closes on Thursday, February 22nd. Analysts expect the company to announce earnings of $0.64 per share for the quarter.
Shares of Emergent Biosolutions (NYSE:EBS) opened at $49.96 on Tuesday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 6.46 and a current ratio of 7.37. The firm has a market cap of $2,470.00, a P/E ratio of 31.23, a P/E/G ratio of 1.07 and a beta of 1.32. Emergent Biosolutions has a 12 month low of $27.94 and a 12 month high of $51.25.
A number of research firms recently weighed in on EBS. Zacks Investment Research downgraded shares of Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 11th. Chardan Capital boosted their price target on shares of Emergent Biosolutions from $47.00 to $53.00 and gave the stock a “buy” rating in a research note on Tuesday, January 16th. Finally, Goldman Sachs Group began coverage on shares of Emergent Biosolutions in a research note on Wednesday, January 24th. They set a “neutral” rating and a $55.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $51.00.
In related news, Chairman Fuad El-Hibri sold 47,983 shares of the business’s stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $41.88, for a total transaction of $2,009,528.04. Following the completion of the sale, the chairman now directly owns 1,550,216 shares of the company’s stock, valued at $64,923,046.08. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Zsolt Harsanyi sold 7,000 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $42.47, for a total transaction of $297,290.00. Following the sale, the director now directly owns 37,077 shares of the company’s stock, valued at $1,574,660.19. The disclosure for this sale can be found here. Over the last three months, insiders have sold 125,722 shares of company stock valued at $5,604,541. 16.50% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://ledgergazette.com/2018/02/20/emergent-biosolutions-ebs-set-to-announce-quarterly-earnings-on-thursday.html.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.